Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Two-year prospective study of onset of action of Mavenclad in highly active relapsing multiple sclerosis
MOH_2018-07-01_002442Phase 4Not yet recruiting
- Sponsor
- Merck KGaA
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cladribine in multiple sclerosis (MS) and relapsing-remitting multiple sclerosis (RRMS), sponsored by Merck KGaA. Primary endpoint: Onset of MAVENCLAD activity on MRI. Planned start Apr 2018; status: not yet recruiting.
02
Drugs
cladribine
03
Conditions
multiple sclerosis (MS)relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on MOH_2018-07-01_002442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-07-01_002442.